

2019

Five-Year Follow Up of a Low Glycaemic Index Dietary Randomised Controlled Trial in Pregnancy—No Long-Term Maternal Effects of a Dietary Intervention

E.C. O'Brien

University College Dublin, Ireland

Aisling A. Geraghty

University College Dublin, Ireland

Elizabeth O'Sullivan

Technological University Dublin, Ireland, liz.osullivan@tudublin.ie

See next page for additional authors

Follow this and additional works at: <https://arrow.tudublin.ie/scschbioart>



Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

O'Brien, E.C., Geraghty, A.A. & O'Sullivan, E.J. (2019). Five-Year Follow Up of a Low Glycaemic Index Dietary Randomised Controlled Trial in Pregnancy—No Long-Term Maternal Effects of a Dietary Intervention. *BJOG: An International Journal of Obstetrics and Gynaecology*, vol. 126, no. 4, pg. 514-524. DOI: 10.1111/1471-0528.15500 doi:10.21427/D7RJ9Z

This Article is brought to you for free and open access by the School of Biological Sciences at ARROW@TU Dublin. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@TU Dublin. For more information, please contact arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie.



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 4.0 License](#)

Authors

E.C. O'Brien, Aisling A. Geraghty, Elizabeth O'Sullivan, J.A. Riordan, Mary K. Horan, Elizabeth Larkin, John Mehegan, P.J. Twomey, and Fionnuala M. McAuliffe

Article Type: Main Research Article

Title Page

Title:

Five Year Follow-Up of a Low GI Dietary Randomised Controlled Trial in Pregnancy - No Long-Term Maternal Effects of a Dietary Intervention

List of authors:

O'Brien, E.C., Geraghty, A.A., O'Sullivan, E.J., Riordan, J.A., Horan, M.K., Larkin, E., Donnelly, J., Mehegan, J., Twomey, P. J., McAuliffe, F. M.

Affiliations:

Dr. Eileen C O'Brien, PhD, UCD Perinatal Research Centre, Obstetrics & Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.

Email: eileen.obrien@ucd.ie

Dr. Aisling A Geraghty, PhD, UCD Perinatal Research Centre, Obstetrics & Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.

Email: aisling.geraghty@ucd.ie

Dr. Mary K Horan, PhD, UCD Perinatal Research Centre, Obstetrics & Gynaecology, School

© 2018 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland. Email: maryhoran21@hotmail.com

Dr. Elizabeth L Larkin, MB, BCH, BAO, UCD Perinatal Research Centre, Obstetrics & Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland. Email: liz.larkin@gmail.com

Dr. Jean M Donnelly, PhD, UCD Perinatal Research Centre, Obstetrics & Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland. Email: jeandonnelly80@yahoo.co.uk

Ms. Julie A Riordan, MSc, Clinical Chemistry, St. Vincent's University Hospital, Dublin, Ireland. Email: J.Riordan@svph.ie

Dr. Elizabeth J O'Sullivan, PhD Email: liz.osullivan@dit.ie

1. UCD Perinatal Research Centre, Obstetrics & Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.
2. School of Biological Sciences, Dublin Institute of Technology, Dublin, Ireland

Dr. John Mehegan, PhD, UCD School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin, Ireland. Email: john.mehegan@ucd.ie

Assoc. Professor, Patrick J Twomey, MB, FRCPATH, FFPATH(RCPI), Clinical Chemistry, St. Vincent's University Hospital, Dublin, Ireland; School of Medicine, University College Dublin, Dublin, Ireland. Email: P.Twomey@st-vincent's.ie

Professor Fionnuala M McAuliffe, MD, FRCOG, UCD Perinatal Research Centre, Obstetrics & Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland. Email: fionnuala.mcauliffe@ucd.ie

Corresponding author:

Professor Fionnuala M McAuliffe, UCD Perinatal Research Centre, Obstetrics & Gynaecology, School of Medicine, University College Dublin, National Maternity Hospital, Dublin, Ireland.

Phone: +353 1 6373216

Email: fionnuala.mcauliffe@ucd.ie

Running Title:

The ROLO Study – Maternal Outcomes at the 5 Year Follow-up

Abstract

Objective: To determine if a dietary intervention in pregnancy had a lasting effect on maternal outcomes of diet, HbA1c and weight retention 5 years' post-intervention; and to establish if modifiable maternal behaviours were associated with these outcomes.

Design: Randomised control trial of low glycaemic index (GI) diet in pregnancy with longitudinal follow-up to 5 years' post-intervention.

Setting: Dublin, Ireland (2007 – 2016)

Population: 403 of 759 (53.1%) were followed-up at 5 years. 370 (intervention n=188; control n=182) were included in this analysis.

Methods: Fasting glucose was measured at 13 and 28 weeks' gestation and HbA1c (mmol/mol) at 5-year follow-up. Weight retention (kg) from early-pregnancy to 5 years' post-intervention was calculated. Dietary intakes, anthropometry and lifestyle factors were measured in pregnancy and 5 years' post-intervention. Multiple linear regression models, controlling for confounders, were used for analysis.

Outcome: Maternal diet, HbA1c and weight retention at 5 years' post-intervention.

Results: There was no difference between the intervention and control at 5 years' post-intervention for any long-term maternal outcomes measured. HbA1c at 5 years' post-intervention was associated with early-pregnancy fasting glucose ($B:1.70$; $CI:0.36-3.04$) and parity ≥ 3 ($B:1.04$; $CI:0.09-1.99$). Weight retention was associated with change in well-being from pregnancy to 5 years ($B:-0.06$; $CI:-0.11--0.02$), gestational weight gain ($B:0.19$; $CI:0.00-0.38$) and GI ($B:0.26$; $CI:0.06-0.46$) at 5 years.

Conclusions

The ROLO low-GI dietary intervention in pregnancy had no impact on maternal dietary intakes, HbA1c or body composition 5 years' post-intervention. Maternal factors and lifestyle behaviours in pregnancy have long-term effects on glucose metabolism and weight retention up to 5 years later.

Funding

Health Research Board; National Maternity Hospital; and EU FP7/2007-2013, EarlyNutrition, Grant 289346.

Keywords

Pregnancy; RCT; Nutrition; Follow-up; maternal weight retention; HbA1c

Tweetable Abstract

Pregnancy factors are associated with maternal glucose metabolism & weight retention 5 years later – findings from the ROLO Study.

Introduction

The low glycaemic index (GI) diet in pregnancy is associated with improvements in dietary intakes¹⁻³, reduced gestational weight gain (GWG)^{1,3}, and improved glycaemic response⁴.

While much research has explored offspring outcomes relating to dietary intakes and GI in pregnancy⁵⁻⁹, there is a paucity of research relating to long-term maternal outcomes following a low-GI diet in pregnancy. Long-term follow-up of pregnancy intervention studies is required to develop an understanding of the impact of maternal diet during a key life stage on future health, and to assess whether lifestyle behaviours are sustained in the postpartum period after the intervention has ended.

Furthermore, the increased physiological demands of pregnancy can act as a biological *stress test for life* to predict a woman's future health¹⁰. Pregnancy is considered a "diabetogenic state" of insulin resistance, exposure to which may result in long-term alterations of normal glucose metabolism¹¹. Gestational diabetes (GDM) increases the risk

of type 2 diabetes in later life ¹²⁻¹⁵, and fasting glucose below levels used to diagnose GDM are associated with increased adverse maternal outcomes ¹⁶. It is unclear, however, if a continuum of increasing fasting blood glucose in pregnancy, below that diagnostic of GDM, increases maternal risk of future diabetes. In addition, weight retention in the period after pregnancy is associated with increased risk of future obesity ^{17,18}. Examining the modifiable behaviours that facilitate or hinder weight loss in the years after pregnancy could assist health care professionals to target specific maternal behaviours ¹⁹.

Whether the immediate and lasting effects of pregnancy on a woman's metabolic health and body composition can be influenced through dietary or environmental manipulation is pertinent for all women, but requires further study. The ROLO study was a randomised control trial (RCT) of a low-GI diet in pregnancy that resulted in improved diet, less GWG and improved glucose tolerance ¹. Due to the longitudinal nature of the ROLO study follow-up, with data collected from 13 weeks' gestation to 5 years' post-intervention, the findings may be used to fill some of the knowledge gaps relating to mothers' health in the years following a dietary intervention.

We aimed to determine if a low-GI dietary intervention had a lasting effect on maternal diet, HbA1c and weight retention 5 years' post-intervention, and to establish if modifiable maternal behaviours, diet and lifestyle factors, in pregnancy and 5 years later were associated with HbA1c and weight retention 5 years' post-intervention.

Methods

Study design

This is a longitudinal study of 370 women originally recruited as part of the ROLO study ¹ at The National Maternity Hospital, Dublin, Ireland. In summary, the ROLO study randomised 800 secundigravida women at approximately 13 weeks' gestation, who had previously delivered a macrosomic infant (>4000 g), to receive either low GI dietary advice or usual

care (no dietary advice) ¹. The primary outcome was birth weight and secondary outcomes were GI, GWG and glucose intolerance ¹. Two weeks post-randomisation, at approximately 15 weeks' gestation, women assigned to the intervention group attended a 2-hour group education session with the research dietitian. Women were taught the principles of healthy eating and a low-GI diet in pregnancy. The research dietitian met with intervention subjects at 28 and 34 weeks' gestation for brief reinforcement of the diet.

At 5 years' post-intervention, all participants were invited to attend a follow-up visit. To be eligible for inclusion participants must have attended the follow-up visit before the child was 5 years and 6 months of age. Institutional ethical approval and informed, written maternal consent were obtained. The study was conducted according to the guidelines laid down in the Declaration of Helsinki.

Of the 759 infants born to study mothers, 403 (53.1%) mother-child dyads were followed-up at the 5-year follow-up visit. A discussion of retention rates at the 5-year follow-up was previously published ²⁰. Of the 403 women, 370 were included in the analysis for weight retention (reasons for exclusion: 17 did not have weight measurement at 5-year follow-up and 16 were pregnant at time of 5-year follow-up). Of the 370 included, 188 were originally randomised to the intervention group and 182 to the control group. For analysis of HbA1c, 161 were included (reasons for exclusion: 241 did not have a blood sample available for HbA1c measurement and 1 had poorly controlled type 2 diabetes that was diagnosed postpartum).

Patient Involvement

In February 2018, the researchers met with the ROLO Family Advisory Committee, a self-selected group of mothers who are involved in the longitudinal follow-up of the ROLO Study. The central theme of this meeting was to discuss key outcomes of importance for the

mothers relating to their own health and their children's health. A report of this meeting is being written for publication at present, but in brief, the mothers had greater concern for outcomes relating to their children than themselves. In terms of maternal health, weight gain during pregnancy and postpartum was not prioritised, however a general blood test in pregnancy, that could predict health risks in later life, was viewed positively and welcomed by the women.

Core Outcome Sets

A core outcome set for longitudinal follow-up of mothers postpartum does not exist.

However, the core outcome sets for diabetes in pregnancy²¹ were consulted when deciding on the outcomes to examine. The primary reason that HbA1c, weight retention and dietary intakes were chosen as outcomes for this piece of research is due to their placement as secondary outcomes in the original RCT (infant macrosomia was the primary outcome of the RCT)¹.

Data collection

Anthropometry and body composition

Height and weight were measured in early pregnancy (13 weeks' gestation) and at the 5-year follow-up visit. Body mass index (BMI) (kg/m²) was calculated. Weight retention was defined as the difference between weight at the early pregnancy visit and weight at the 5-year follow-up visit. GWG was calculated by subtracting the measured weight at the first antenatal visit from the final weight in pregnancy (measured at 38, 40 or 41 week's gestation). The 2009 Institute of Medicine (IOM) guidelines for total GWG²² were used to categorise GWG. Bioimpedance analysis (BIA) was used to measure fat-free mass and fat

mass at the 5-year follow-up visit using the ImpediMed Imp™ SFB7 device (ImpediMed Ltd, Brisbane, Australia).

Dietary intakes

Dietary intakes in pregnancy were collected using 3-day food diaries. All food and beverages consumed over three consecutive days were recorded by participants during each trimester. To estimate habitual dietary intakes over the previous year, participants completed the 2002 SLÁN 148-item food frequency questionnaire (FFQ), plus questions relating to milk²³. The questionnaire was validated in an Irish population²⁴ and in pregnancy²⁵. Dietary data were entered into dietary analysis software NetWISP version 3.0 (Tinuviel Software, Llanfechell, Anglesey, UK). The NetWISP food composition database was derived from the 6th edition of McCance and Widdowson's food composition tables²⁶.

At the 5-year follow-up, participants completed the 2007 SLÁN 150-item FFQ to estimate dietary intakes over the past two years²⁷. The questionnaire was validated in an Irish population²⁷. Standard food portions were assigned to each food item according to the Food Standards Agency portion sizes book²⁸. The nutrient profile for each food item was set using data from using the updated 2015 McCance and Widdowson's The Composition of Foods Integrated Dataset²⁹.

Demographics and lifestyle

Data were collected on maternal age, parity, number of years since last pregnancy, breastfeeding for the study child, maternal educational attainment and smoking. The World Health Organisation-5 (WHO-5) well-being index was used to assess well-being in pregnancy and at the 5-year visit³⁰. Physical activity was assessed in pregnancy using the 1998 SLÁN questionnaire, which was based on the Godin Leisure-Time Exercise

Questionnaire³¹. At the 5-year follow-up visit, participants completed the short International Physical Activity Questionnaire (IPAQ)³². Metabolic equivalents (METs) were calculated³³, and participants were classified as low, medium or high. Minutes spent walking was recorded at both time points.

Blood sample

At 13 and 28 weeks' gestation, fasting blood samples were collected. A glucose challenge test (GCT), 1-hour post a 50 g glucose load, was performed at 28 weeks' gestation. Glucose intolerance in pregnancy was classified as 28 weeks' gestation fasting glucose ≥ 5.1 mmol/L or 28 weeks' gestation GCT > 7.8 mmol/L., as previously used in the ROLO Study¹. Fasting glucose results were also categorised according to the HAPO glucose categories¹⁶. At the 5-year follow-up visit a non-fasting blood sample was collected and HbA1c concentration was determined using Tina-quant HemoglobinA1c Generation 3, analysed on a Roche Cobas 6000 (Roche Diagnostics GmbH, Mannheim, Germany).

Statistical Analysis

Data were assessed for normality using the Kolmogorov-Smirnov test and visual inspection of histograms. Non-normally distributed variables were log transformed for regression analysis. We included the maximum number of participants with complete data for each set of analysis. Correlations between maternal characteristics and HbA1c and weight change were initially examined. Bivariate associations with significance of $P < 0.1$ were further analysed using multiple regression models. Models were created using a forced-enter approach and were adjusted for confounders. Confounders were chosen *a priori*, based on the literature and correlations observed in the data. Models exploring HbA1c as an outcome were controlled for grouping (intervention), maternal age at the 5-year follow-up, BMI at the 5-year follow-up, ethnicity, energy (kcal/day) at the 5-year follow-up and physical activity

(IPAQ) at the 5-year follow-up. Models exploring weight retention as an outcome were controlled for grouping (intervention), maternal education, parity, smoking status at 5 years, energy (kcal/day) at the 5-year follow-up, physical activity (IPAQ) at the 5-year follow-up and GWG. The model testing GWG as an independent variable was additionally controlled for early-pregnancy BMI. To improve interpretation of the results, the variables for energy were scaled (per 100 kcal/day) for the multiple linear regression analysis.

Funding

This study was supported by the Health Research Centre for Health and Diet Research (Health Research Board Ireland), The National Maternity Hospital Medical Fund and the European Union's Seventh Framework Programme (FP7/2007-2013), project EarlyNutrition under grant agreement no. 289346. The funding sources had no involvement in the study.

Results

Maternal Characteristics and Dietary Intakes

Half (n = 188 [50.8%]) of the women who attended the 5-year follow-up ROLO study visit had been originally randomised to the intervention group of the ROLO RCT and 182 (50.2%) to the control group. Maternal characteristics are detailed in Table 1. Weight remained generally stable from early pregnancy (mean [SD]: 72.0 [12.9] kg) to 5-years' post-intervention (mean [SD]: 71.8 [13.5] kg), with mean (SD) postpartum weight retention of -0.1 (6.1) kg (Table 1). Substantial weight retention of ≥ 5 kg was observed in 59 (16.1%) women. At the 5-year follow-up, mean (SD) HbA1c was 31.46 (2.70) mmol/mol and 5.03 (0.25) % (Table 1). Two women had a HbA1c concentration between 39 – 47 mmol/mol, classified as pre-diabetes according to the American Diabetes Association guidelines³⁴. Dietary GI was

similar between the food diaries in pregnancy and the FFQ instrument completed at the 5-year follow-up visit (mean [SD] in trimester 3: 56.75 [3.96] and 56.11 [3.82], respectively).

Among those who attended the 5-year follow-up, no significant differences between the intervention and control groups existed in terms of GWG, excessive GWG as per the IOM guidelines, BMI at 5 years, weight retention, glucose metabolism in pregnancy and HbA1c at 5 years (Table 2). Based on the three-day food diaries completed in pregnancy, GI, glycaemic load (product of GI and carbohydrate intake), carbohydrate (g/day) and sugar (g) were similar between the intervention and control in trimester 1 (pre-intervention) and were significantly lower in the intervention group in trimester 2 and 3 (post-intervention). In all trimesters of pregnancy the intervention group reported consuming significantly less energy (kcal/day) and greater percentage energy from protein (Table 2, S1 and S2). However, the FFQ completed at the 5 years' post-intervention did not detect differences in GI nor any other dietary intakes between the intervention and control group (Table 2, S1 and S2).

HbA1c at 5 Years

The positive correlation between fasting glucose in pregnancy (categorised as per the HAPO study) and HbA1c at 5 years' post-intervention is described in Figure S1 of supporting information.

On multiple linear regression, controlling for confounders, a 1 mmol/L increase in early-pregnancy fasting glucose was associated with a 1.70 (95% CI: 0.36 - 3.04) mmol/mol increase in HbA1c; a one-category increase in HAPO glucose categories in early pregnancy was associated with a 0.53 (95% CI: 0.16 - 0.90) mmol/L increase in HbA1c; and a trend was observed ($P = 0.050$) for an association between glucose intolerance at 28 weeks'

gestation and a 1.06 (95% CI: 0.00 - 2.12) mmol/mol increase in HbA1c (Table 3). Each additional child, after the index study child (second child), was associated with a 0.83 (95% CI: 0.11 - 1.55) mmol/mol increase in HbA1c at the 5-year visit, and having 3 or more children was associated with a 1.04 (95% CI: 0.09 - 1.99) mmol/mol higher HbA1c at the 5-year visit than those with 2 children (Table 3).

Weight Retention

On multiple linear regression, controlling for confounders, a 1 percentage score increase in well-being from pregnancy to the 5-year visit was associated with 0.06 (95% CI: 0.02 - 0.11) kg less weight retention; a 1 kg increase in GWG was associated with 0.19 (95% CI: 0.00 - 0.38) kg higher weight retention (additionally controlling for early-pregnancy BMI); a 1 percentage increase in energy from protein at 5-year visit was associated with 0.30 (95% CI: 0.03 - 0.56) kg less weight retention; and 1 unit increases in GI and glycaemic load at the 5-year visit were associated with higher weight retention (0.26 [95% CI: 0.06 - 0.46] and 0.04 [95% CI: 0.01 - 0.07] kg, respectively) (Table 4). Weight retention was positively associated with BMI ($B = 0.38$; 95% CI: 0.21 - 0.56) and fat mass ($B = 0.22$; 95% CI: 0.10 - 0.33) at the 5-year visit (Table 4).

Lost to Follow-up

Compared to women who were lost to follow-up, those who attended the 5-year visit were significantly older in pregnancy (mean [SD]: 31.74 [4.42] vs. 33.08 [3.92], $P < 0.001$), more likely to have completed tertiary education (48.7% vs. 61.1%, $P = 0.003$), had a lower early-pregnancy BMI (kg/m^2) (mean [SD]: 27.38 [5.35] vs. 26.10 [4.44], $P < 0.001$) and higher early-pregnancy fasting glucose (mmol/L) (mean [SD]: 4.42 [0.38] vs. 4.49 [0.36], $P = 0.015$) (Table S1). No significant differences were observed in randomisation grouping, GWG or well-being (Table S1). Women who attended the 5-year follow-up visit reported higher

energy intakes throughout pregnancy, but no other nutrients were consistently different between those who attended and those lost to follow-up (Table S3).

Discussion

Main Findings

This was the 5-year longitudinal follow-up of women who participated in the ROLO RCT of a low-GI diet in pregnancy. The intervention and control groups did not differ in any outcomes measured at 5 years. Higher fasting glucose in early pregnancy and parity were positively associated with HbA1c at the 5-year follow-up. Lower GWG and an improved sense of well-being over time were associated with less weight retention. Habitual dietary intakes of higher energy from protein, lower GI and lower GL in the two years prior to the 5-year follow-up visit were also associated with less weight retention.

Strengths and Limitations

The longitudinal nature of the ROLO study and the well-characterised cohort provide novel findings relating to mothers' metabolism and body composition in the years following a dietary intervention. Strengths of this study include the objective measurement of anthropometry by trained researchers and the prospective collection of detailed dietary and biochemical data at multiple time points. In terms of generalisability, it is probable that our findings are not applicable to populations other than educated, Caucasian women living in a developed country. Furthermore, all women had previously delivered a macrosomic infant. In total, 53.1% (403/759) of the ROLO study participants completed the 5-year follow-up. This is not dissimilar to the follow-up rates of similar research studies; at 6-months postpartum the UPBEAT study followed-up 45.9%⁶; at 12 months postpartum the PIN study followed-up

47.0%³⁵; and at 3 – 6 years Project Viva followed-up 68.1%³⁶. The differences in maternal characteristics between those who attended and lost-to-follow-up are discussed above and must be considered when interpreting these findings. Weight remained generally stable from early pregnancy to 5-years' post-intervention which is less than that quoted in the literature for 3 years' (2.2 kg)³⁷ and 7 years' (2.1 kg)¹⁷ post-partum. It is possible that those who were not followed-up had greater weight retention. In terms of statistical analysis, some of the R² adjusted in the multiple linear regression models are approaching zero or are negative, meaning that these models have low predictive power. Adjustment of the significance level for multiple testing was not used, increasing the risk of observing a chance finding. Finally, due to the observational nature of this study, we cannot infer causality based on these findings.

Interpretation

HbA1c at 5 Years

We observed that increasing early-pregnancy fasting glucose and HAPO glucose categories were positively associated with HbA1c 5 years later. Both the HAPO study and a recent systematic review by Farrar *et al.* reported that a linear relationship exists between glucose concentration in pregnancy and adverse perinatal outcomes, with no obvious threshold observed above which risk of adverse outcomes are substantially increased^{16,38}. It could be hypothesised that a continuum of increasing fasting blood glucose in pregnancy potentially poses longer term risks than those outlined by the aforementioned studies. In our study, a trend was observed between glucose intolerance (using a 50 g GCT) at 28 weeks' gestation and HbA1c 5 years later ($P = 0.050$). Our findings are supported by previous research that indicated an abnormal GCT was associated with lower insulin sensitivity at 3 years postpartum³⁷. These results suggest that subtle variations in fasting glucose and glucose tolerance in pregnancy are associated with HbA1c up to 5 years later; however, whether this

has a meaningful impact on long-term diabetes risk requires further research. Future longitudinal studies may benefit from using a 75 g oral glucose tolerance test in pregnancy, the current recommended test for diagnosis of GDM ³⁹.

Additionally, increasing parity was associated with HbA1c at the 5-year visit, in keeping with literature that has observed a greater risk of developing type 2 diabetes as parity increases ^{11,40,41}. It has been theorised that repeated exposure the “diabetogenic state” of insulin resistance, characteristic of pregnancy, may result in long-term alteration of normal glucose metabolism ¹¹.

Weight Retention

Each kilogram increase in GWG was associated with 0.19 kg increase in weight retention at 5 years' post-intervention. Similar rates have been quoted in the literature ^{42,43}, while others have suggested that first trimester GWG is more strongly associated with postpartum weight retention than second or third trimester GWG ⁴³. It would seem prudent to offer pregnant women lifestyle interventions that reduce GWG. Nevertheless, the ROLO intervention, which was successful in reducing GWG, was not associated with weight retention at 5 years' post-intervention. Perhaps an intervention that included reinforcement in the postpartum period may have been more successful in preventing weight retention.

We observed increased well-being from pregnancy to the 5-year visit was associated reduced weight retention. Anxiety in pregnancy, stressful events in the early postpartum period and postpartum depression are associated with increased weight retention ^{35,44,45}, suggesting that a woman's mental health is of great importance in terms of weight retention in the years following the birth of her children. Optimising well-being through the provision of

appropriate support, such as parenting support, stress relief classes, self-management strategies and behaviour change could have the potential to alleviate stress and thus, lessen weight retention ⁴⁶. It should also be noted that medications used to treat and manage anxiety and mental health conditions may be a confounding factor in the association between poor mental health and weight gain.

Weight retention 5 years' post-intervention was not associated with being a member of the intervention group, dietary GI or glycaemic load in pregnancy. While our findings are similar to those of the UPBEAT 6-month follow-up study ⁶, they are contrary to findings from the Danish National Birth Cohort which demonstrated an association between increasing glycaemic load in pregnancy and greater weight retention at 18 months' post-pregnancy ⁴⁷. We did, however, observe that higher GI and glycaemic load reported at the 5-year visit (reflective of the previous two years) were positively associated with weight retention. This suggests that the glycaemic effect of current dietary intakes is of greater relevance to weight status than diet in pregnancy, and also advocates for the potential benefit of reinforcements of a low-GI dietary intervention in the postpartum period.

In terms of sustainability of the ROLO study, the maternal benefits seemed to extend to 3 and 6 months' post-intervention, as previously published ^{48,49}, but not up to 5 years' post-intervention. These results are broadly similar to what was reported in the previous pregnancy RCTs, which have observed short-term (4 – 6 month) ^{6,7}, but not long term (up to 2 years) ⁵⁰ maintenance of lifestyle behaviours and health benefits. To be sustainable, additional interventions that reinforce dietary changes are likely required in the postpartum period ⁵¹.

Conclusions

Fasting glucose and GWG in pregnancy are associated with HbA1c and weight retention 5 years later, adding to the hypothesis that pregnancy is a window to future maternal health.

The ROLO low-GI dietary intervention in pregnancy did not have a lasting impact on dietary intakes, HbA1c or body composition 5 years later; however the value of improving dietary intakes in pregnancy and the postpartum years should not be underestimated given the long lasting impact that GWG potentially has on future maternal body composition. To maintain positive behaviours adopted during pregnancy, it is likely that additional interventions that reinforce dietary changes are required postpartum, an area which requires substantial research.

Acknowledgements

We would like to thank the ROLO mothers who participated in the study and to the ROLO Families Advisory Committee for their contributions to the research agenda of the ROLO Follow-up study.

Disclosure of Interests

The authors do not have any conflicts of interest. Completed disclosure of interest forms are available to view online as supporting information.

Contribution to Authorship

EOB, AG were involved in the conception, planning, carrying out, analysing and writing up of the work. MK, EL, JD were involved in the conception, planning, carrying out and writing up of the work. JR and PT were involved in carrying out, analysing and writing up of the work.

EOS and JM were involved in analysing and writing up of the work. FMcA oversaw all aspects of the work and is responsible for the final content.

Details of Ethics Approval

The ROLO study and 5-year follow-up study were conducted according to the guidelines laid down in the Declaration of Helsinki. Ethical approval for the ROLO study was obtained from the National Maternity Hospital ethics committee in December 2006 (no reference number). Ethical approval for the 5-year follow-up study was obtained in October 2012 from the ethics committee of Our Ladies Children's Hospital, Crumlin, Dublin, Ireland (reference number: GEN/279/12).

Funding

The ROLO study was funded by the Health Research Board, Ireland. The follow-up study was supported by the HRB Centre for Health and Diet Research, The National Maternity Hospital Medical Fund and the European Union's Seventh Framework Programme (FP7/2007-2013), project EarlyNutrition under grant agreement number 289346.

References

1. Walsh JM, McGowan CA, Mahony R, Foley ME, McAuliffe FM. Low glycaemic index diet in pregnancy to prevent macrosomia (ROLO study): randomised control trial. *BMJ*; 2012;345:e5605.
2. Markovic TP, Muirhead R, Overs S, Ross GP, Louie JCY, Kizirian N, et al.

Randomized Controlled Trial Investigating the Effects of a Low–Glycemic Index Diet on Pregnancy Outcomes in Women at High Risk of Gestational Diabetes Mellitus: The GI Baby 3 Study. *Diabetes Care*; 2016;39(1):31–8.

3. Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, Goff L, et al. Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial. *Lancet Diabetes Endocrinol*; 2015;3(10):767–77.
4. Zhang R, Han S, Chen G-C, Li Z-N, Silva-Zolezzi I, Parés GV, et al. Effects of low-glycemic-index diets in pregnancy on maternal and newborn outcomes in pregnant women: a meta-analysis of randomized controlled trials. *Eur J Nutr*; 2018;57(1):167–177.
5. Horan MK, Donnelly JM, McGowan CA, Gibney ER, McAuliffe FM. The association between maternal nutrition and lifestyle during pregnancy and 2-year-old offspring adiposity: analysis from the ROLO study. *J Public Heal*; 2016;24(5):427–36.
6. Patel N, Godfrey KM, Pasupathy D, Levin J, Flynn AC, Hayes L, et al. Infant adiposity following a randomised controlled trial of a behavioural intervention in obese pregnancy. *Int J Obes*; 2017;41(7):1018–26.
7. Dodd JM, Cramp C, Sui Z, Yelland LN, Deussen AR, Grivell RM, et al. The effects of antenatal dietary and lifestyle advice for women who are overweight or obese on maternal diet and physical activity: the LIMIT randomised trial. *BMC Med*; 2014;12:161.
8. Kizirian N V., Kong Y, Muirhead R, Brodie S, Garnett SP, Petocz P, et al. Effects of a low-glycemic index diet during pregnancy on offspring growth, body composition, and vascular health: a pilot randomized controlled trial. *Am J Clin Nutr*; 2016;103(4):1073–82.
9. Murrin C, Shrivastava A, Kelleher CC, Lifeways Cross-generation Cohort Study Steering Group. Maternal macronutrient intake during pregnancy and 5 years

postpartum and associations with child weight status aged five. *Eur J Clin Nutr*; 2013;67(6):670–9.

10. Williams D. Pregnancy: a stress test for life. *Curr Opin Obstet Gynecol*; 2003;15(6):465–71.
11. Mueller NT, Mueller NJ, Odegaard AO, Gross MD, Koh WP, Yuan JM, et al. Higher parity is associated with an increased risk of type-II diabetes in Chinese women: the Singapore Chinese Health Study. *BJOG*; 2013;120(12):1483–9.
12. Greenberg L, Moore T, Murphy H. Gestational diabetes mellitus: Antenatal variables as predictors of postpartum glucose intolerance. *Obstet Gynecol*; 1995;86(1):97–101.
13. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care*; 2002;25(10):1862–8.
14. Bellamy L, Casas J-P, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet*; 2009;373(9677):1773–9.
15. Feig DS, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. *CMAJ*; 2008;179(3):229–34.
16. HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcomes. *N Engl J Med*; 2008;358(19):1991–2002.
17. Kirkegaard H, Stovring H, Rasmussen KM, Abrams B, Sørensen TIA, Nohr EA. Maternal weight change from prepregnancy to 7 years postpartum-the influence of behavioral factors. *Obesity*;2015;23(4):870–8.
18. Rooney BL, Schauberger CW. Excess pregnancy weight gain and long-term obesity: one decade later. *Obstet Gynecol*; 2002;100(2):245–52.
19. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *Lancet*; 2016;387(10026):1377–96.

- Accepted Article
20. O'Brien EC, Geraghty AA, McAuliffe FM. Successful strategies to improve follow-up for longitudinal birth cohort studies. *Contemp Clin Trials*; 2017;57:8–9.
 21. Egan AM, Galjaard S, Maresh MJA, Loeken MR, Napoli A, Anastasiou E, et al. A core outcome set for studies evaluating the effectiveness of prepregnancy care for women with pregestational diabetes. *Diabetologia*; 2017;60(7):1190–6.
 22. Institute of Medicine. National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines. *Weight Gain During Pregnancy* [Internet]. Washington (DC): National Academies Press (US); 2009.
 23. Kelleher C, Saoirse NG, Daly E, Corrigan H, Galvin M, Friel S, et al. The National Health & Lifestyle Surveys 2003. Regional Results of the National Health & Lifestyle Surveys SLÁN (Survey of Lifestyle, Attitudes & Nutrition) & HBSC (Health Behaviour in School Aged Children). Dublin; 2003.
 24. Harrington JM. Validation of a Food Frequency Questionnaire as a tool for assessing nutrient intake. National University of Ireland, Galway. Galway; 1997.
 25. McGowan CA, Curran S, McAuliffe FM. Relative validity of a food frequency questionnaire to assess nutrient intake in pregnant women. *J Hum Nutr Diet*; 2014;27 Suppl 2:167–74.
 26. Food Standards Agency. McCance and Widdowson's *The Composition of Foods Sixth Summary Edition*. Cambridge: Royal Society of Chemistry; 2002.
 27. Harrington J, Perry I, Lutomski J, Morgan K, McGee H, Shelley E, et al. SLÁN 2007: Survey of Lifestyle, Attitudes and Nutrition in Ireland. *Dietary Habits of the Irish Population*. *Psychol Reports*. 2008;6.
 28. Food Standards Agency. *Food Portion Sizes*. London: The Stationary Office; 2002.
 29. Public Health England. McCance and Widdowson's *The Composition of Foods Integrated Dataset 2015*. London; 2015.
 30. World Health Organization. *Wellbeing Measures in Primary Health Care: the DepCare Project: Report on a WHO Meeting Stockholm, Sweden 12-13 February*

1998. Copenhagen; 1998.
31. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. *Can J Appl Sport Sci*; 1985;10(3):141–6.
32. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International Physical Activity Questionnaire: 12-Country Reliability and Validity. *Med Sci Sport Exerc*; 2003;35(8):1381–95.
33. International Physical Activity Questionnaire [Internet]. Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ)– Short Form. 2005 [cited 2018 Aug 23]. Available from: <https://sites.google.com/site/theipaq/scoring-protocol>
34. American Diabetes Association. Standards of Medical Care in Diabetes - 2017. Classification and Diagnosis of Diabetes. *Diabetes Care*; 2016;40(Supplement 1):S11 LP-S24.
35. Siega-Riz AM, Herring AH, Carrier K, Evenson KR, Dole N, Deierlein A. Sociodemographic, perinatal, behavioral, and psychosocial predictors of weight retention at 3 and 12 months postpartum. *Obesity*; 2010;18(10):1996–2003.
36. Oken E, Baccarelli AA, Gold DR, Kleinman KP, Litonjua AA, De Meo D, et al. Cohort profile: project viva. *Int J Epidemiol*;2015;44(1):37–48.
37. Stuebe AM, Mantzoros C, Kleinman K, Gillman MW, Rifas-Shiman S, Seely EW, et al. Gestational glucose tolerance and maternal metabolic profile at 3 years postpartum. *Obstet Gynecol*; 2011;118(5):1065–73.
38. Farrar D, Simmonds M, Bryant M, Sheldon TA, Tuffnell D, Golder S, et al. Hyperglycaemia and risk of adverse perinatal outcomes: systematic review and meta-analysis. *BMJ*; 2016;354:i4694.
39. International Association of Diabetes and Pregnancy Study Groups Consensus Panel (IADPSG), Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations

on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care*. 2010;33(3):676-682.

40. Araneta MRG, Barrett-Connor E. Grand multiparity is associated with type 2 diabetes in Filipino American women, independent of visceral fat and adiponectin. *Diabetes Care*; 2010;33(2):385–9.
41. Nicholson WK, Asao K, Brancati F, Coresh J, Pankow JS, Powe NR. Parity and Risk of Type 2 Diabetes: The Atherosclerosis Risk in Communities study. *Diabetes Care*; 2006;29(11):2349–54.
42. Althuisen E, van Poppel MNM, de Vries JH, Seidell JC, van Mechelen W. Postpartum behaviour as predictor of weight change from before pregnancy to one year postpartum. *BMC Public Health*. 2011;11:165.
43. Walter JR, Perng W, Kleinman KP, Rifas-Shiman SL, Rich-Edwards JW, Oken E, et al. Associations of trimester-specific gestational weight gain with maternal adiposity and systolic blood pressure at 3 and 7 years postpartum. *Am J Obs Gynecol*; 2015;212(4):499 e1-499 e12.
44. Bogaerts AFL, Van den Bergh BRH, Witters I, Devlieger R. Anxiety during early pregnancy predicts postpartum weight retention in obese mothers. *Obesity*; 2013; 21(9):1942-9
45. Herring SJ, Rich-Edwards JW, Oken E, Rifas-Shiman SL, Kleinman KP, Gillman MW. Association of postpartum depression with weight retention 1 year after childbirth. *Obesity*; 2008;16(6):1296–301.
46. Harrison CL, Lombard CB, Teede HJ. Limiting postpartum weight retention through early antenatal intervention: the HeLP-her randomised controlled trial. *Int J Behav Nutr Phys Act*; 2014;11:134.
47. Knudsen VK, Heitmann BL, Halldorsson TI, Sørensen TIA, Olsen SF. Maternal dietary glycaemic load during pregnancy and gestational weight gain, birth weight and postpartum weight retention: a study within the Danish National Birth Cohort. *Br*

J Nutr;2013;109(8):1471–8.

48. Horan MK, McGowan CA, Gibney ER, Donnelly JM, McAuliffe FM. Maternal diet and weight at 3 months postpartum following a pregnancy intervention with a low glycaemic index diet: Results from the ROLO randomised control trial. *Nutrients*; 2014;6(7):2946–55.
49. Horan MK, McGowan CA, Gibney ER, Byrne J, Donnelly JM, McAuliffe FM. Maternal Nutrition and Glycaemic Index during Pregnancy Impacts on Offspring Adiposity at 6 Months of Age--Analysis from the ROLO Randomised Controlled Trial. *Nutrients*; 2016;8(1): pii: E7
50. Moses RG, Luebke M, Petocz P, Brand-Miller JC. Maternal diet and infant size 2 y after the completion of a study of a low-glycemic-index diet in pregnancy. *Am J Clin Nutr*;2007;86(6):1806.
51. Vesco KK, Leo MC, Karanja N, Gillman MW, McEvoy CT, King JC, et al. One-year postpartum outcomes following a weight management intervention in pregnant women with obesity. *Obesity*;2016;24(10):2042–9.

Table/Figure Caption List

Tables

Table 1. Maternal characteristics of those who attended the 5-year ROLO follow-up

Table 2. Maternal characteristics at the 5-year follow-up visit (intervention vs. control)

Table 3. Multiple linear regression models for associations between maternal characteristics and HbA1c (mmol/mol)

Table 4. Multiple linear regression models for associations between maternal characteristics and weight retention (kg)

Supporting Tables and Figures

Table S1. Maternal nutrient intakes in pregnancy from three-day food diaries (intervention vs. control)

Table S2. Maternal nutrient intakes in pregnancy and at 5-year follow-up visit using food frequency questionnaires (intervention vs. control)

Table S3. Maternal characteristics (attended vs. did not attend the 5-year follow-up visit)

Figure S1. HbA1c at 5-year follow-up and fasting blood glucose categorised according to the HAPO fasting glucose categories in (a) early pregnancy and at (b) 28 weeks' gestation.

Table 1. Maternal Characteristics of those who attended the 5-Year ROLO Follow-Up

Demographics	N	
Age at delivery, (years) ^a	370	33.17 (3.95)
Age at 5-year follow-up visit, (years) ^a	370	38.36 (3.96)
Parity ^a	370	2.48 (0.64)
≥3 children ^b		152 (41.08)
Years since birth of youngest child ^c	360	5.07 (2.46)
≥2 years ^b		311 (86.39)
Education, completed tertiary ^b	324	199 (61.42)
Anthropometry		
Weight, early pregnancy, (kg) ^a	368	71.98 (12.88)
Weight, final pregnancy, (kg) ^a	297	84.80 (13.14)
Weight, 5-year follow-up visit, (kg) ^a	368	71.82 (13.45)
Gestational weight gain, (kg) ^a	296	12.83 (4.23)
Inadequate ^b		62 (20.95)
Adequate ^b		96 (32.43)
Excessive ^b		138 (46.62)
Weight retention from early pregnancy to 5 years, (kg) ^a	366	-0.10 (6.05)
Height, (cm) ^a	369	165.91 (6.31)
Early-pregnancy BMI, (kg/m ²) ^a	368	26.16 (4.49)
5-year follow-up visit BMI, (kg/m ²) ^a	368	26.04 (4.67)
Bioelectrical Impedance		
Fat-free mass, 5-year follow-up visit, (kg) ^a	231	48.47 (7.01)
Fat-free mass %, 5-year follow-up visit ^a	231	68.09 (6.77)
Fat mass, 5-year follow-up visit, (kg) ^a	231	23.47 (8.50)
Fat mass %, 5-year follow-up visit ^a	231	31.86 (6.82)
Physical Activity		
Pregnancy, walk for at least 30 minutes, (days/week) ^c	262	3.0 (3.0)
5-year follow-up visit, total METS ^a	323	1762.32 (1863.01)
High IPAQ ^b		98 (30.30)
Medium IPAQ ^b		129 (39.90)
Low IPAQ ^b		96 (29.70)
5-year follow-up visit, walking, (minutes/week) ^a	323	234.83 (305.19)

Glucose Metabolism

Early pregnancy fasting glucose (mmol/L) ^a	356	4.50 (0.36)
28 weeks' gestation fasting glucose (mmol/L) ^a	347	4.49 (0.46)
1-hour GCT, 28 weeks' gestation, (mmol/L) ^a	363	6.55 (1.48)
Glucose intolerant, 28 weeks' gestation, Yes ^b	366	92 (25.14)
HbA1c, 5-year follow-up visit, (%) ^a	160	5.03 (0.25)
HbA1c, 5-year follow-up visit, (mmol/mol) ^a	160	31.46 (2.70)

Well-Being (WHO-5) Percentage Score

Pregnancy ^a	321	58.32 (15.14)
5-year follow-up visit ^a	321	62.69 (14.44)
Change pregnancy to 5-year follow-up visit ^a	287	4.35 (15.47)

Breastfeeding Practices

No breastfeeding ^b	338	124 (36.70)
<26 weeks ^b		116 (34.30)
≥26 weeks ^b		98 (29.00)

Glycaemic Index

Trimester 1 ^a	288	57.63 (3.90)
Trimester 2 ^a	288	56.70 (3.68)
Trimester 3 ^a	288	56.75 (3.96)
Mid-pregnancy FFQ ^a	325	54.50 (3.20)
5-year follow-up visit ^a	326	56.11 (3.82)

Data presented as: ^a Mean (SD), ^b n (%), ^c median (IQR)

BMI: body mass index; IPAQ: international physical activity questionnaire; IQR: interquartile range; METS: metabolic equivalents; SD: standard deviation;

Table 2. Maternal Characteristics at the 5-Year Follow-Up Visit (Intervention vs. Control)

	Grouping	N		P
Demographics				
Age, 5-year follow-up, (years) ^a	Control	182	38.75 (3.87)	0.062
	Intervention	188	37.98 (4.01)	
Weight				
Gestational weight gain, (kg) ^a	Control	142	13.27 (4.48)	0.084
	Intervention	154	12.42 (3.96)	
Exceed IOM weight gain guidelines ^b	Control	142	72 (50.70)	0.200
	Intervention	154	66 (42.86)	
Weight, 5-year follow-up, (kg) ^a	Control	182	71.74 (13.86)	0.910
	Intervention	186	71.89 (13.08)	
BMI, 5-year follow-up, (kg/m ²) ^a	Control	182	25.98 (4.75)	0.799
	Intervention	186	26.10 (4.60)	
Weight Retention from Early Pregnancy to 5 years				
Weight retention, (kg) ^a	Control	181	-0.10 (5.94)	0.989
	Intervention	185	-0.09 (6.18)	
% weight retention ^a	Control	181	-0.06 (7.82)	0.801
	Intervention	185	0.15 (8.00)	
Bioelectrical Impedance				
Fat-free mass, 5-year follow-up, (kg) ^a	Control	117	48.21 (7.05)	0.578
	Intervention	114	48.73 (7.00)	
Fat-free mass %, 5-year follow-up ^a	Control	117	68.39 (7.06)	0.501
	Intervention	114	67.79 (6.48)	
Fat mass, 5-year follow-up, (kg) ^a	Control	117	23.15 (9.04)	0.565
	Intervention	114	23.79 (7.94)	
Fat mass %, 5-year follow-up ^a	Control	117	31.52 (7.15)	0.445
	Intervention	114	32.21 (6.48)	
Glucose Metabolism				
Fasting glucose, early pregnancy, (mmol/L) ^a	Control	173	4.50 (0.33)	0.952
	Intervention	183	4.50 (0.38)	
Fasting glucose, 28 weeks' gestation, (mmol/L) ^a	Control	168	4.48 (0.49)	0.699

	Intervention	179	4.50 (0.44)	
	Control	177	6.58 (1.48)	0.642
1-hour GCT, 28 weeks' gestation, (mmol/L) ^a	Intervention	186	6.51 (1.48)	
	Control	178	48 (26.97)	0.506
Glucose intolerant, 28 weeks' gestation ^a	Intervention	188	44 (23.40)	
	Control	82	31.61 (2.95)	0.460
HbA1c, 5-year follow-up, (mmol/mol) ^a	Intervention	78	31.30 (2.42)	
Glycaemic Index				
	Control	150	57.66 (3.94)	0.894
Trimester 1 ^a	Intervention	138	57.60 (3.88)	
	Control	150	57.38 (3.42)	0.001
Trimester 2 ^a	Intervention	138	55.96 (3.82)	
	Control	150	57.39 (3.95)	0.004
Trimester 3 ^a	Intervention	138	56.05 (3.87)	
	Control	160	54.63 (3.37)	0.473
Mid-pregnancy FFQ ^a	Intervention	166	54.37 (3.03)	
	Control	158	55.80 (3.85)	0.156
5-year follow-up visit ^a	Intervention	168	56.40 (3.78)	

Data presented as: ^a Mean (SD), ^b n (%)

SD: standard deviation; GCT: glucose challenge test; BMI: body mass index; Glucose intolerant at 28 weeks' gestation: fasting glucose ≥ 5.1 mmol/L or GCT > 7.8 mmol/L

Table 3. Multiple Linear Regression Models for Associations between Maternal Characteristics and HbA1c (mmol/mol)

	N	B (%Δ)^a	P	95% CI	R² Adj	Model P
Demographics and Lifestyle						
Parity	136	0.83	0.025	(0.11, 1.55)	0.06	0.029
≥3 children	136	1.04	0.033	(0.09, 1.99)	0.06	0.035
Years since birth of youngest child ^a	134	-0.68 (-46.44%)	0.086	(-1.46, 0.10)	0.05	0.065
Walk for at least 30 minutes in pregnancy, (days/week) ^a	99	1.20 (232.01%)	0.018	(0.21, 2.18)	0.00	0.398
Glucose Metabolism						
Fasting glucose, Early pregnancy, (mmol/L)	129	1.70	0.013	(0.36, 3.04)	0.07	0.020
Fasting glucose, Early pregnancy, HAPO glucose categories	129	0.53	0.006	(0.16, 0.90)	0.09	0.011
Fasting glucose, Early pregnancy, HAPO glucose categories, >4.4mmol/L	129	0.79	0.106	(-0.17, 1.75)	0.05	0.071
Fasting glucose, 28 weeks' gestation, (mmol/L)	130	0.91	0.109	(-0.21, 2.03)	0.05	0.054
Fasting glucose, 28 weeks' gestation, HAPO glucose categories	130	0.34	0.055	(-0.01, 0.69)	0.06	0.036
1-hour GCT, 28 weeks' gestation, (mmol/L)	132	0.29	0.076	(-0.03, 0.61)	0.06	0.046
Glucose intolerant, 28 weeks' gestation	133	1.06	0.050	(0.00, 2.12)	0.06	0.039
Dietary intakes						
Energy						
Trimester 1, (100 kcal/day)	116	0.16	0.008	(0.04, 0.27)	0.01	0.351
Trimester 2, (100 kcal/day)	117	0.16	0.006	(0.04, 0.27)	0.01	0.304
Trimester 3, (100 kcal/day)	116	0.13	0.028	(0.01, 0.25)	-0.01	0.582
Protein						

Trimester 2, (g/day)	117	0.03	0.021	(0.01, 0.06)	-0.01	0.518
Trimester 1, (%energy)	116	-0.21	0.014	(-0.38, -0.04)	0.00	0.452
Fat						
Trimester 2, (g/day)	117	0.02	0.046	(0.00, 0.04)	-0.02	0.684
Trimester 3, (g/day)	116	0.02	0.028	(0.00, 0.04)	-0.01	0.577
Carbohydrate						
Trimester 1, (g/day)	116	0.01	0.003	(0.00, 0.02)	0.02	0.207
Trimester 2, (g/day)	117	0.01	0.005	(0.00, 0.02)	0.02	0.261
Trimester 3, (g/day)	116	0.01	0.075	(0.00, 0.02)	-0.03	0.784
Glycaemic Index						
Trimester 1	112	0.13	0.048	(0.00, 0.25)	-0.02	0.628
Glycaemic Load						
Trimester 1	112	0.02	0.002	(0.01, 0.03)	0.04	0.127
Trimester 2	112	0.02	0.024	(0.00, 0.03)	0.00	0.489
Trimester 3	112	0.01	0.106	(0.00, 0.03)	-0.03	0.789
Sugar						
Trimester 1, (g/day)	116	0.01	0.021	(0.00, 0.03)	-0.01	0.529
Trimester 2, (g/day)	117	0.01	0.027	(0.00, 0.03)	-0.01	0.567

Confounders: grouping (intervention), maternal age at the 5-year follow-up, BMI at the 5-year follow-up, ethnicity, energy (kcal) at the 5-year follow-up and physical activity (IPAQ) at the 5-year follow-up. ^a %Δ: percentage change for logged variables (non-normally distributed). GCT: glucose challenge test. Glucose intolerant at 28 weeks' gestation: fasting glucose ≥5.1 mmol/L or GCT >7.8 mmol/L

Table 4. Multiple Linear Regression Models for Associations between Maternal Characteristics and Weight Retention (kg)

	N	B (%Δ)^a	P	95% CI	R² Adj	Model P
Demographics and Lifestyle						
Years since birth of youngest child ^a	268	-2.09 (-87.64%)	0.027	(-3.94, -0.24)	0.08	0.001
Change pregnancy to 5-year Well-Being (WHO-5) percentage score	263	-0.06	0.011	(-0.11, -0.02)	0.07	0.002
Anthropometry						
Final pregnancy weight, (kg)	218	-0.08	0.015	(-0.14, -0.01)	0.07	0.002
Gestational weight gain, (kg)	218	0.19	0.049	(0.00, 0.38)	0.08	0.001
Body Mass Index, early pregnancy, (kg/m ²)	270	-0.25	0.007	(-0.43, -0.07)	0.08	0.001
Body Mass Index, 5-year follow-up visit, (kg/m ²)	270	0.38	0.000	(0.21, 0.56)	0.13	<0.001
Fat-free mass, 5-year follow-up visit, (kg)	168	0.09	0.186	(-0.05, 0.23)	-0.04	0.910
Fat-free mass %, 5-year follow-up visit	168	-0.25	0.001	(-0.39, -0.11)	0.04	0.099
Fat mass, 5-year follow-up visit, (kg)	168	0.22	0.000	(0.10, 0.33)	0.06	0.048
Fat mass %, 5-year follow-up visit	168	0.25	0.001	(0.11, 0.39)	0.04	0.099

Glucose Metabolism

Fasting glucose, 28 weeks' gestation, (mmol/L)	253	-1.39	0.127	(-3.18, 0.40)	0.04	0.038
Fasting glucose, 28 weeks' gestation, HAPO glucose categories	253	-0.30	0.312	(-0.89, 0.28)	0.04	0.060
1-hour GCT, 28 weeks' gestation, (mmol/L)	264	-0.64	0.027	(-1.20, -0.07)	0.06	0.006

Dietary intakes

Protein

Trimester 1, (g/day)	241	-0.03	0.240	(-0.07, 0.02)	0.04	0.055
Trimester 1, (%energy)	241	-0.16	0.229	(-0.42, 0.10)	0.04	0.054
Trimester 2, (%energy)	244	-0.07	0.633	(-0.37, 0.23)	0.03	0.075
5-year follow-up FFQ, (%energy)	270	-0.30	0.027	(-0.56, -0.03)	0.07	0.003

Carbohydrate

Trimester 2, (g/day)	244	0.01	0.225	(-0.01, 0.02)	0.04	0.050
Trimester 1, (%energy)	241	0.09	0.214	(-0.05, 0.23)	0.04	0.052
Trimester 2, (%energy)	244	0.04	0.572	(-0.10, 0.19)	0.03	0.073
5-year follow-up FFQ, (%energy)	270	0.11	0.071	(-0.01, 0.23)	0.06	0.006

Glycaemic Index

5-year follow-up FFQ	270	0.26	0.012	(0.06, 0.46)	0.08	0.002
Glycaemic Load						
Trimester 2	230	0.02	0.259	(-0.01, 0.04)	0.03	0.076
5-year follow-up FFQ	270	0.04	0.017	(0.01, 0.07)	0.07	0.002
Sugar						
Trimester 1, (g/day)	241	0.02	0.139	(-0.01, 0.04)	0.04	0.042
Trimester 2, (g/day)	244	0.01	0.190	(-0.01, 0.04)	0.04	0.046

Confounders: grouping (intervention), maternal education, years since birth of youngest child, smoking status at 5 years, energy (kcal) at the 5-year follow-up, physical activity (IPAQ) at the 5-year follow-up, and GWG. GWG model additionally controlled for early-pregnancy BMI. Years since birth of youngest child model additionally controlled for parity. ^a%Δ: percentage change for logged variables (non-normally distributed). GCT: glucose challenge test; FFQ: food frequency questionnaire. 5-year follow-up visit FFQ estimated dietary intakes over the past two years